

Requests for allowances for desulfurization during 1998 are due no later than April 1, 1999. Allowances allocated in 1999 will have a compliance year of 1999.

Dated: May 7, 1998.

Edward Callahan,

Acting Director, Office of Atmospheric Programs.

[FR Doc. 98-12848 Filed 5-13-98; 8:45 am]

BILLING CODE 6560-50-U

FEDERAL ELECTION COMMISSION

Sunshine Act Meeting

* * * * *

DATE & TIME: Tuesday, May 19, 1998 at 10:00 a.m.

PLACE: 999 E Street, NW., Washington, DC.

STATUS: This meeting will be closed to the public.

ITEMS TO BE DISCUSSED:

Compliance matters pursuant to 2 U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C. § 437g, § 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

* * * * *

DATE & TIME: Wednesday, May 20, 1998 at 10:00 a.m.

PLACE: 999 E Street, NW., Washington, DC (Ninth Floor).

STATUS: This hearing will be open to the public.

MATTER BEFORE THE COMMISSION: Perot '96, Inc.,

DATE & TIME: Thursday, May 21, 1998 at 10:00 a.m.

PLACE: 999 E Street, NW. Washington, DC (Ninth Floor).

STATUS: This Meeting Will Be Open to the Public.

ITEMS TO BE DISCUSSED:

Correction and Approval of Minutes.

Advisory Opinion 1998-07: Pennsylvania Democratic Party by C.M. Tartaglione, Acting Chairman.

Advisory Opinion 1998-08: Iowa Democratic Party by Michael Peterson, Chairman.

Advisory Opinion 1998-09: New Mexico Republican Party by John Dendahl, Chairman.

Petition for Rulemaking on Qualified Nonprofit Corporations: Draft Notice of Disposition.

Administrative Matters.

PERSON TO CONTACT FOR INFORMATION:

Mr. Ron Harris, Press Officer,
Telephone: (202) 694-1220.

Marjorie W. Emmons,

Secretary of the Commission.

[FR Doc. 98-13018 Filed 5-12-98; 12:34 p.m.]

BILLING CODE 6715-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services announces the following advisory committee meeting.

Name: National Committee on Vital and Health Services (NCVHS) Executive Subcommittee.

Times and Dates: 9:00 a.m.-5:00 p.m., May 21, 1998.

Place: Conference Room 503A, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC. 20201.

Status: Open.

Purpose: The Executive Subcommittee will hold a work planning session on May 21. In addition to reviewing the status of current work plans and activities, the Subcommittee will plan future priorities and activities and consider future work plans and schedules. The Subcommittee also will plan the agenda for the June 16-17 meeting of the full committee.

Contact Person for More Information:

Substantive information as well as an agenda for the meeting and a roster of committee members may be obtained by visiting the NCVHS website (<http://aspe.os.dhhs.gov/ncvhs>), where an agenda will be posted prior to the meeting. You may also call James Scanlon, NCVHS Executive Staff Director, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 440-D, Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201, telephone (202) 690-7100, or Marjorie S. Greenberg, Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone (301) 436-7050.

Note: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, individuals without a government identification card may need to have the guard call for an escort to the meeting room.

Dated: May 6, 1998.

James Scanlon,

Director, Division of Data Policy.

[FR Doc. 98-12762 Filed 5-13-98; 8:45 am]

BILLING CODE 4151-04-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Advisory Committee on HIV and STD Prevention: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92-463) of October 6, 1972, that the CDC Advisory Committee on HIV and STD Prevention of the Department of Health and Human Services, has been renewed for a 2-year period beginning May 12, 1998, through May 11, 2000.

For further information, contact Ronald O. Valdiserri, M.D., M.P.H., Deputy Director, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road NE, MS E-07, Atlanta, Georgia 30333, phone 404-639-8002, fax 404-639-8600, e-mail rov1@cdc.gov.

Dated: May 7, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-12826 Filed 5-13-98; 8:45 am]

BILLING CODE 4163-19-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Safety and Occupational Health Study Section: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Task Group Session of the Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH).

Time and Date: 8 a.m.-5:30 p.m., August 5-7, 1998.

Place: Embassy Suites Hotel, 1900 Diagonal Road, Alexandria, Virginia, 22314.

Status: Open 8 a.m.-8:30 a.m. August 5, 1998; Closed 8:30 a.m.-5:30 p.m. August 5, 1998; Closed 8 a.m.-5:30 p.m. August 6, 1998; Closed 8 a.m.-5:30 p.m. August 7, 1998.

Purpose: A Task Group of the SOHSS will review, discuss, and evaluate grant application(s) received in response to the sponsoring Institute's numbered solicitations as follows: Request For Application Number 98044 entitled, "Implementation of the National Occupational Research Agenda (NORA)," which pertains to broad-based research endeavors outlined as follows: (a)

Causal research to identify and investigate the relationships between hazardous working conditions and associated occupational disease and injury; (b) the nature and magnitude of special risk factors experienced by older and/or minority workers; (c) methods research to develop more sensitive means of evaluating hazards at work sites; and (d) evaluations of the effectiveness of new approaches or combinations of techniques such as control technologies and personal protective equipment, work organization changes, worker participation programs, and training in reducing or eliminating traumatic injuries and work-related musculoskeletal injuries.

Request For Application Number 98030 entitled, "Occupational Radiation and Energy-Related Health Research Grants," which pertains to research endeavors outlined as follows:

(a) Research to identify and investigate the relationships between health outcomes and occupational exposure to radiation and other hazardous agents; (b) epidemiological methods research relevant to energy-related occupational health research; and (c) research related to assessing occupational exposures. The focus of proposed research should reflect the following topical areas, emphasizing field research: (1) Retrospective exposure assessment; (2) radiation measurement issues; (3) non-cancer morbidity and mortality outcomes; (4) meta-analysis and combined analysis methodologies; (5) uncertainty analysis; (6) effects of measurement error on risk estimates; (7) studies of current workers; and (8) risk communication and worker outreach.

It is the intent of NIOSH to support broad-based research endeavors in keeping with the Institute's program goals as outlined above which will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses. It is anticipated that research funded will promote these program goals.

Matters To Be Discussed: The meeting will convene in open session from 8–8:30 a.m. on August 5, 1998, to address matters related to the conduct of Study Section business. The remainder of the meeting will proceed in closed sessions. The purpose of the closed sessions is for the Task Group to consider safety and occupational health grant applications related to the cited solicitation. These portions of the meeting will be closed to the public in accordance with provisions set forth in section 552(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92–463.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, Office of the Director, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone 304/285–5979.

Dated: May 7, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–12825 Filed 5–13–98; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Oncologic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on June 1, 1998, 8:30 a.m. to 5:30 p.m., and June 2, 1998, 8 a.m. to 5:30 p.m.

Location: Gaithersburg Hilton, Grand Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4090, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

Agenda: On June 1, 1998, the committee will discuss: (1) New drug application (NDA) 20–892 AD 32 (valrubicin 40 milligrams/milliliter), Anthra Pharmaceuticals, Inc., indicated for the treatment of refractory carcinoma *in situ* of the urinary bladder; and (2) NDA supplement 20–449/S–005 Taxotere® (docetaxel) for injection concentrate, Rhone-Polenc Rorer Pharmaceuticals, Inc., indicated for the treatment of patients with locally advanced or metastatic breast cancer who have failed previous chemotherapy. On June 2, 1998, the committee will discuss: (1) Biologics license application (BLA) 97–1325 ONTAK™ (denileukin diftitox) injection (DAB₃₈₉ IL–2), Seragen, Inc.,

indicated for the treatment of cutaneous T-cell lymphoma (CTCL); and (2) NDA supplement 20–671/S–004 Hycamtin® (topotecan HCl) for injection, SmithKline Beecham Pharmaceuticals, indicated for the second-line treatment of patients with small cell lung cancer.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 22, 1998. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:15 a.m., on June 1, 1998, and between approximately 8:15 a.m. and 8:45 a.m., on June 2, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 15, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 7, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–12756 Filed 5–13–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98D–0284]

Guidance for Industry on Classifying Resubmissions in Response to Action Letters; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Classifying Resubmissions in Response to Action Letters." This guidance explains how the agency will classify resubmissions of new drug applications (NDA's) and license applications (LA's) and specifies the agency's response timeframes. The guidance also recommends procedures for making resubmissions.

DATES: Written comments may be submitted on the guidance by August 12, 1998. General comments on the agency guidance documents are welcome at any time.